Berk Hande, Oztoprak Nefise, Kizilates Filiz, Kurtoğlu Erdal, Seremet Keskin Aysegul
Infectious Diseases and Clinical Microbiology Clinic, Antalya Education and Research Hospital, Antalya, TUR.
Infectious Diseases and Clinical Microbiology Clinic, Anatolia Hospital Lara, Antalya, TUR.
Cureus. 2024 Jul 1;16(7):e63570. doi: 10.7759/cureus.63570. eCollection 2024 Jul.
Extended-spectrum beta-lactamase-producing (ESBL-E) infections are a major source of mortality and morbidity in patients with hematologic cancers. One of the most significant risk factors for bacterial illness is prior colonization with resistant germs. Empiric usage of carbapenems is recommended for the treatment of infections in patients with a positive colonization history.
We aimed to determine the outcome of empirical carbapenem (de-escalation) versus non-carbapenem (escalation) therapy in adult hematology patients who have rectal extended-spectrum beta-lactamase positive ESBL-E colonization.
Two hundred three rectal swab cultures were collected from 130 patients, admission or during hospitalization between June 2014 and May 2015. Patients were followed till January 2016 for future infections due to ESBL-E. Empirical antibiotic treatment was started according to the patient's medical condition without consideration of previous colonization status. Stable patients received empirical escalation therapy. All-cause and early mortality of infections are analyzed.
Seventy-three (36%) swabs were positive for ESBL-E. Patients with rectal ESBL-E colonization were defined as cases; patients without colonization were defined as controls. Prospective infection due to ESBL-E in the case and control group was 6.8% and 2.3%, respectively. No statistically significant relation was found between colonization and prospective infection due to ESBL-E (p=0.110). There was no all-cause or early mortality in prospective infections with ESBL-E. Among case patients, one patient each died from all-cause mortality in the escalation (n=55) and de-escalation (n=3) group. The all-cause mortality in the antibiotic switch group (n=30) was eight, including five patients in the early mortality group although the bacteriologic agents were susceptible to the given antibiotics.
In our institution, rectal colonization with ESBL-E was high, but contracting an infection due to ESBL-E was surprisingly low. Colonization with ESBL-E may not necessarily end with an infection in some situations. In stable patients, disregarding colonization features before empirical therapy did not seem to be inappropriate.
产超广谱β-内酰胺酶(ESBL-E)感染是血液系统癌症患者死亡和发病的主要原因。细菌性疾病最重要的危险因素之一是先前被耐药菌定植。对于有定植史阳性的患者,建议经验性使用碳青霉烯类药物治疗感染。
我们旨在确定在直肠产超广谱β-内酰胺酶阳性(ESBL-E)定植的成年血液学患者中,经验性碳青霉烯类药物(降阶梯)治疗与非碳青霉烯类药物(升阶梯)治疗的效果。
2014年6月至2015年5月期间,从130例患者入院时或住院期间收集了203份直肠拭子培养物。对患者进行随访直至2016年1月,观察是否发生因ESBL-E引起的未来感染。根据患者的病情开始经验性抗生素治疗,不考虑先前的定植状态。病情稳定的患者接受经验性升阶梯治疗。分析感染的全因死亡率和早期死亡率。
73份(36%)拭子ESBL-E呈阳性。直肠ESBL-E定植的患者被定义为病例组;未定植的患者被定义为对照组。病例组和对照组因ESBL-E导致的前瞻性感染分别为6.8%和2.3%。未发现定植与ESBL-E导致的前瞻性感染之间存在统计学显著相关性(p=0.110)。ESBL-E前瞻性感染中无全因死亡或早期死亡。在病例组患者中,升阶梯组(n=55)和降阶梯组(n=3)各有1例患者死于全因死亡。抗生素转换组(n=30)的全因死亡为8例,其中早期死亡组有5例患者,尽管细菌病原体对所用抗生素敏感。
在我们机构中,ESBL-E直肠定植率较高,但因ESBL-E感染的发生率出奇地低。在某些情况下,ESBL-E定植不一定会导致感染。对于病情稳定的患者,经验性治疗前不考虑定植特征似乎并无不妥。